Trials / Completed
CompletedNCT02121717
Study of Chiglitazar Compare With Placebo in Type 2 Diabetes Patients
Phase III Study of Chiglitazar in Patients With Type 2 Diabetes Mellitus and Insufficient Glycemic Control Despite Diet and Exercise -- A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Trial
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 535 (actual)
- Sponsor
- Chipscreen Biosciences, Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of Chiglitazar, compare with placebo.
Detailed description
The efficacy and safety will be compared between Chiglitazar and placebo after treatment of 24 weeks. The long term efficacy and safety of Chiglitazar will be evaluated after 52 weeks treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Chiglitazar | Take orally |
| DRUG | Placebo | Take orally |
Timeline
- Start date
- 2014-06-01
- Primary completion
- 2017-11-01
- Completion
- 2017-11-01
- First posted
- 2014-04-23
- Last updated
- 2019-10-25
Locations
26 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02121717. Inclusion in this directory is not an endorsement.